iBio Inc. reported financial results for Q1 FY2025 ended September 30, 2024, with net loss from continuing operations narrowing to $4.0 million ($0.46 per share) compared to $5.1 million ($4.24 per share) in Q1 FY2024. Total operating expenses decreased to $4.1 million from $5.2 million, driven by lower research & development and general & administrative costs.The company ended the quarter with $11.3 million in cash and cash equivalents, which is expected to fund operations into Q1 FY2026. Management is evaluating options to extend cash runway, including focusing on select product candidates, potential asset sales/licensing, and additional capital raises. The company continues to advance its AI-powered antibody discovery platform and preclinical pipeline targeting oncology and metabolic diseases.iBio's technology stack includes AI-guided epitope steering and antibody optimization capabilities, with programs advancing in areas like anti-myostatin antibodies for obesity/muscle wasting and IBIO-101 for cancer immunotherapy. The company recently entered collaborations with AstralBio and other partners to leverage its AI platform while pursuing strategic options to strengthen its financial position.

iBio Inc. reported financial results for Q1 FY2025 ended September 30, 2024, with net loss from continuing operations narrowing to $4.0 million ($0.46 per share) compared to $5.1 million ($4.24 per share) in Q1 FY2024. Total operating expenses decreased to $4.1 million from $5.2 million, driven by lower research & development and general & administrative costs.The company ended the quarter with $11.3 million in cash and cash equivalents, which is expected to fund operations into Q1 FY2026. Management is evaluating options to extend cash runway, including focusing on select product candidates, potential asset sales/licensing, and additional capital raises. The company continues to advance its AI-powered antibody discovery platform and preclinical pipeline targeting oncology and metabolic diseases.iBio's technology stack includes AI-guided epitope steering and antibody optimization capabilities, with programs advancing in areas like anti-myostatin antibodies for obesity/muscle wasting and IBIO-101 for cancer immunotherapy. The company recently entered collaborations with AstralBio and other partners to leverage its AI platform while pursuing strategic options to strengthen its financial position.